综合一区欧美国产,99国产麻豆免费精品,九九精品黄色录像,亚洲激情青青草,久久亚洲熟妇熟,中文字幕av在线播放,国产一区二区卡,九九久久国产精品,久久精品视频免费

Global EditionASIA 中文雙語Fran?ais
World
Home / World / Asia-Pacific

Japan OKs stem cells for corneal disease

By Wang Xu in Tokyo | China Daily | Updated: 2019-03-07 09:38
Share
Share - WeChat
Hideyuki Okano (L), a Japanese physiology professor and the current dean of Keio University School of Medicine and Masaya Nakamura, a Japanese orthopedics professor, attend a press conference to mention about iPS clinical research in Tokyo on Feb 18, 2019. [Photo/IC]

Japan's Health Ministry on Tuesday granted permission for world's first clinical test with artificially derived stem cells for the treatment of a corneal disease that causes decreasing vision, local media reported.

The corneal test, the sixth case authorized by the Japanese government using induced pluripotent stem (iPS) cells, will be conducted by a team of researchers from Osaka University led by Professor Kohji Nishida.

With artificial cultivation, the iPS cells can grow into any type of body tissues.

According to Nishida, the team will transplant a 0.05-mm-thick sheet-like corneal tissue produced from iPS cells into the eyes of four patients, all of whom suffer from diseases that bring corneal haze or decreased vision.

The first transplant operation could be carried out as early as June, Nishida said, adding the treatment might come into common use within five to six years.

The researchers will keep an eye on the safety and the effectiveness of the operation for one year after the surgery and are required to submit reports to the Health Ministry after the studies on two of the patients are completed.

The Osaka University team's research would be a breakthrough for patients with corneal disease as there are not enough corneas for transplants due to limited number of donors, officials from the Health Ministry said. They cited data that a total of 1,600 patients are currently waiting for corneal donations in Japan.

"I will promote clinical research as safely and promptly as possible and develop it for standard medical care," Nishida told reporters after the panel discussion.

Developed by a team led by Kyoto University's Shinya Yamanaka, the iPS cells can theoretically grow into any type of body tissue.

Other cases using iPS cells already approved by the Japanese government include treatments for platelet transfusion, Parkinson's disease, heart disease and damaged spinal cords

In recognition for his discovery that "mature cells can be reprogrammed to become pluripotent", Yamanaka was awarded the Nobel Prize in Physiology and Medicine in 2012.

In 2014, backed by the government, Japan's Riken institute conducted the world's first clinical test using iPS cells by transplanting artificial retina cells into an individual with a another type of eye disease.

Kyodo News contributed to this story.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
五寨县| 涟源市| 蕲春县| 大厂| 兰溪市| 南安市| 雅江县| 忻城县| 岳阳市| 遵化市| 若羌县| 水富县| 林口县| 宜川县| 桑植县| 龙门县| 收藏| 武宁县| 凯里市| 巍山| 三门县| 镇江市| 连江县| 叙永县| 桐柏县| 疏附县| 西贡区| 四平市| 射阳县| 清水县| 江津市| 伊金霍洛旗| 曲麻莱县| 黔西县| 蒲江县| 孝义市| 辽源市| 虹口区| 高邑县| 青龙| 洛南县|